This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Exametazime
DrugBank Accession Number
DB11179
Background

Exametazime is a diagnostic radiopharmaceutical agent commonly used for the preparation of Tc99m Exametazime injection. It acts as a chelating agent for the radioisotope technetium-99m to form a cationic complex. It is used in the detection of altered regional cerebral perfusion and for the radiolabeling of autologous leukocytes.

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 272.393
Monoisotopic: 272.221226158
Chemical Formula
C13H28N4O2
Synonyms
  • Exametazima
  • Exametazime
External IDs
  • DL HM-PAO
  • DL-HM-PAO

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
No interactions found.

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Drax Exametazime
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Exametazime HMPAOInjection, powder, lyophilized, for solution1 mg/1IntravenousAnazao Health Corporation2012-07-01Not applicableUS flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Exametazime HMPAOExametazime (1 mg/1)Injection, powder, lyophilized, for solutionIntravenousAnazao Health Corporation2012-07-01Not applicableUS flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
G29272NCKL
CAS number
105613-48-7
InChI Key
BPNZYADGDZPRTK-UDUYQYQQSA-N
InChI
InChI=1S/C13H28N4O2/c1-9(11(3)16-18)14-7-13(5,6)8-15-10(2)12(4)17-19/h9-10,14-15,18-19H,7-8H2,1-6H3/b16-11+,17-12+/t9-,10-/m1/s1
IUPAC Name
(E)-N-[(3R)-3-[(3-{[(2R,3E)-3-(hydroxyimino)butan-2-yl]amino}-2,2-dimethylpropyl)amino]butan-2-ylidene]hydroxylamine
SMILES
C[C@@H](NCC(C)(C)CN[C@H](C)C(\C)=N\O)C(\C)=N\O

References

General References
  1. FDA Approved Drug Products: Drax Exametazime (kit for the preparation of technetium Tc99m exametazime for leukocyte labeling) for intravenous use [Link]
PubChem Substance
347911145
ChemSpider
7830987
RxNav
62153
ChEBI
31586
ChEMBL
CHEMBL1615781
Wikipedia
Technetium_(99mTc)_exametazime

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Unknown StatusDiagnosticVascular Prosthesis Infection1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, powder, lyophilized, for solutionIntravenous0.3 mg
Injection, powder, for solutionIntravenous
InjectionIntravenous0.5 MG
Injection, powder, for solutionIntravenous0.5 mg
Injection, powder, lyophilized, for solutionIntravenous
PowderIntravenous
Injection, powder, lyophilized, for solutionIntravenous1 mg/1
SolutionIntravenous0.5 mg
KitIntravenous500 Mikrogramm
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.25 mg/mLALOGPS
logP0.59ALOGPS
logP0.93ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)9.68ChemAxon
pKa (Strongest Basic)8.48ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area89.24 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity76.95 m3·mol-1ChemAxon
Polarizability31.26 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at December 03, 2015 16:51 / Updated at May 14, 2021 01:05